Fri, May 13, 2022

Matthew Barcus Maintained (VINC) at Strong Buy with Decreased Target to $11 on, May 13th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-11-on-may-13th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Matthew Barcus of Chardan Capital, Maintained "Vincerx Pharma, Inc." (VINC) at Strong Buy with Decreased Target from $14 to $11 on, May 13th, 2022.

Matthew has made no other calls on VINC in the last 4 months.



There is 1 other peer that has a rating on VINC. Out of the 1 peers that are also analyzing VINC, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $28 on, Wednesday, March 30th, 2022